Valuation: Genomma Lab Internacional, S.A.B. de C.V.

Market Cap 14.85B 851M 743M 682M 636M 1.21B 80.97B 1.23B 8.22B 3.18B 39.72B 3.19B 3.12B 137B P/E 2026 *
6.94x
P/E 2027 * 6.86x
Enterprise Value 18.71B 1.07B 936M 860M 802M 1.52B 102B 1.55B 10.35B 4.01B 50.04B 4.02B 3.94B 172B EV / Sales 2026 *
1.02x
EV / Sales 2027 * 0.95x
Free-Float
68.95%
Yield 2026 *
5.26%
Yield 2027 * 7.21%
04-23 Genomma Lab Internacional, S.A.B. de C.V., Q1 2026 Earnings Call, Apr 23, 2026
04-23 Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
02-26 Genomma Lab Internacional, S.A.B. de C.V., Q4 2025 Earnings Call, Feb 26, 2026
02-25 Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
12-09 Genomma Lab Internacional Announces Fourteenth Dividend Payment, Payable on December 23, 2025 CI
25-10-23 Genomma Lab Internacional, S.A.B. de C.V., Q3 2025 Earnings Call, Oct 23, 2025
25-10-21 Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-07-24 Genomma Lab Internacional, S.A.B. de C.V., Q2 2025 Earnings Call, Jul 24, 2025
25-07-23 Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-06-24 Genomma Lab Internacional, S.A.B. De C.V. Announces Twelfth Quarterly Dividend Payment, Payable on July 1, 2025 CI
25-06-04 Genomma Lab Successfully Issued the Lab 25 and Lab 25-2 Unsecured Bonds for A Total Amount of $1.2 Billion Pesos, Which Will Be Used to Prepay Liabilities, Including the Full Early Amortization of the Lab 23 Bond CI
25-05-01 Genomma Lab Internacional, S.A.B. de C.V., Q1 2025 Earnings Call, May 02, 2025
25-04-30 Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
1 day-2.37%
1 week+0.93%
Current month+1.33%
1 month-2.12%
3 months-18.90%
6 months-15.06%
Current year-14.87%
1 week 14.65
Extreme 14.65
15.7
1 month 14.24
Extreme 14.24
15.7
Current year 14.24
Extreme 14.24
19.48
1 year 14.24
Extreme 14.24
23.6
3 years 12.39
Extreme 12.39
29.18
5 years 12.39
Extreme 12.39
29.18
10 years 11.1
Extreme 11.1
29.18
Manager TitleAgeSince
Chief Executive Officer - 2023-04-11
Director of Finance/CFO - 2015-11-30
Investor Relations Contact - 2019-09-30
Director TitleAgeSince
Chairman - 1996-10-29
Director/Board Member - 2010-07-05
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-2.37%+0.93%-26.35%+15.38% 868M
+1.86%+7.65%+55.77%+158.84% 1,063B
+3.57%+7.42%+69.09%+58.92% 611B
+3.99%+7.37%+36.87%+93.77% 444B
-1.20%-1.94%+26.41%+20.22% 324B
+4.94%+3.39%+39.92%+28.93% 285B
+2.42%+1.60%+30.06%+42.24% 283B
+2.47%+5.18%-24.80%-39.60% 219B
+3.55%+6.05%+26.04%+68.52% 195B
+4.21%+6.00%+17.72%+70.33% 156B
Average +1.87%+4.02%+25.07%+51.75% 358.16B
Weighted average by Cap. +1.85%+5.08%+41.53%+80.67%

Financials

2026 *2027 *
Net sales 18.32B 1.05B 917M 842M 785M 1.49B 99.88B 1.51B 10.14B 3.93B 48.99B 3.94B 3.85B 169B 19.24B 1.1B 963M 884M 824M 1.56B 105B 1.59B 10.64B 4.12B 51.44B 4.14B 4.05B 177B
Net income 2.14B 122M 107M 98.17M 91.55M 174M 11.65B 176M 1.18B 458M 5.71B 459M 449M 19.69B 2.25B 129M 113M 103M 96.44M 183M 12.27B 186M 1.25B 483M 6.02B 484M 473M 20.74B
Net Debt 3.86B 221M 193M 177M 165M 314M 21.05B 319M 2.14B 828M 10.33B 830M 812M 35.58B 3.46B 198M 173M 159M 148M 281M 18.88B 286M 1.92B 743M 9.26B 745M 729M 31.91B
Logo Genomma Lab Internacional, S.A.B. de C.V.
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
Employees
1,643
Date Price Change Volume
26-07-02 MX$15.23 -2.37% 3,487,891
26-07-01 MX$15.60 +3.79% 3,977,498
26-06-30 MX$15.03 +0.80% 6,164,745
26-06-29 MX$14.91 -0.33% 2,412,960
26-06-26 MX$14.96 -0.86% 3,986,049
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
15.23MXN
Average target price
24.40MXN
Spread / Average Target
+60.21%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LAB B Stock